View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 28, 2011

Impax Completes Patient Enrolment for IPX066 Drug Trial

Impax Pharmaceuticals has completed patient enrolment in a Phase III comparitive study of IPX066 versus immediate-release carbidopa-levodopa and entacapone in subjects with advanced Parkinson's disease. IPX066, an investigational extended-release capsule formulation of carbidopa-levo

By cms admin

Impax Pharmaceuticals has completed patient enrolment in a Phase III comparitive study of IPX066 versus immediate-release carbidopa-levodopa and entacapone in subjects with advanced Parkinson’s disease.

IPX066, an investigational extended-release capsule formulation of carbidopa-levodopa, has been developed in collaboration with GlaxoSmithKline.

The randomised, double-blind, two-treatment, two-period crossover study enrolled 110 people, 90 of whom were entered into the comparative phase of the study, following which they will be enrolled in a six-month open-label extension phase.

In the study, the primary efficacy parameter is the per cent “off time” during waking hours based on the patients’ Parkinson’s disease diaries.

The Phase III study results are expected in late August 2011.

The company said that it plans to file a new drug application for IPX066 in the fourth quarter of 2011.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology